i Northwest Bioanalytical Study No.

PFOS 3M FLUOROCHEMICAL SUBMISSIONS February, 2002 - May, 2004 ENVIRONMENTAL STUDIES Click on Study Title to View Report Perfluorooctanesulfonate PAGE 1, 2, 3, 4, 5 Summary and Other Environmental and Health Assessment of Perfluorooctane Sulfonic Acid and Its Salts, 3M, August 20, 2003.

3M Company EPl-0013 Page lo f 36 FINAL REPORT Epidemiology Medical Department 3M Company S t Paul.

A M & 'W lf BIODEGRADATION TEST SUBSTANCE Identity: Perfluorooctanesulfonylamido(ethyl)acetate; may also be referred to as PFOSAA, FC-128 or as the major component of FC-127, FC-129, FC-109, FC-109-Xor R1904.

New Datatiff AR.&3.6-062.5 Completion of two generation reproductive studies for perfluorooctane sulfonate and EpetFrfOluSoEro, oacntdancerossusl-ffoonsatetreinstgufdoyllow up to Pharmacokinetics during pregnancy studies Second species (rabbit) teratology study Completion of 180 day repeat dose study in primates with one year recovery 3M Medical Department March 7,2000 I Pending Two-year feeding studies EtFOSE - In-life done 4/2000 Perfluorooctane sulfonate - In-life done 4/2000 6 month and one year recovery after 180 day feeding study in primates ADME study in primates 3M Medical Department March 7,2000 Pending Human sera studies Health claims study Update mortality study Mechanistic and metabolic studies 3M Medical Department March 7,2000 3 ResultsFo- sRteerpirnogdSutcutidoines/Cross- N0.O4 EmLg/fkogr/dreopfrpoedruflcutiovreoeonctdapnoeinstuslfonate is Perinatal mortality is predominantly a pup effect rather than a maternal effect Effect on cholesterol metabolism is hypothesized mechanism - studies planned to test hypothesis 3M Medical Department March 7,2000 ResultsD-oPseriSmtuatdeyRepeat 0.15 mg/kg/d well tolerated for 6 months (apparent NOEL) Cholesterol level decreased at perfluorooctane sulfonate serum concentrations greater than 100 ppm (in the high dose group) 2 deaths in males at 0.75 mg/kg/d that were apparently compound relateyd At the high dose (0.75 mg/kg/d) body weight liver weight and liver morphology were affected 3M Medical Department March 7,2000 r Results - Sera Concentrations Perfluorooctane sulfonate serum concentrations increase linearly with dose in l8o3w-1a0n7dpmpmid) dose groups (16-20 ppm and Perfluorooctane sulfonate serum tchoencheinghtradtoisoengs rfooullpows, ewditahbmipahxaimsicumcurvvaeluiens at 250-300 ppm 3M Medical Department March 7,2000 Background "19O6r8ganic fluorine" reported in human sera in 3M medical surveillance from 1976 to present Aconmalpyosuesndfosrdsopseecaiffitcerflu19o9ro2o-rdgeatneicction limit less than 50 ppb in 1997 Mcoocncuutltepimpaltpeiooanrnaaarlllyyysseiesxrpfaroossamemd)hpfilsientsodr(nipcoeanrfn-ludorooctane sulfonate at less than 50 ppb 3M Medical Department March 7,2000 7 Background Various studies, including medical surveillance, done over the last 25 years In the last two years have used outside experts to identify needs and help define studies Have created Scientific Advisory Panel for additional review 3M Medical Department March 7,2000 2 Review - Data in Health Effects Paper ADME Metabolic precursors to perfluorooctane sulfonate Repeat dose feeding studies - rat and primate Genotoxicity Teratology 3M Medical Department March 7,2000 Review - Data in Health Effects Paper (Continued) Cross-sectional study of exposed employees Mortality study at production plant site Irnepterroidmucdtaivtae fsrtoumdy2-generation Interim data from new repeat dose primate study 3M Medical Department March 7,2000 10 Results The additional data does not suggest a health risk associated with the levels of perfluor loctane sulfonate found in the sera of occupationally or non-occupationally exposed employees, blood bank samples or commercially available serum. 3M Medical Department March 7,2000 //

/4 & U 6 " /% ?

AR226-2207 Debbie J Mulrooney 11/02/2001 09:43 AM To: Robert F Pinchot/DEV/AE/DuPont@DuPont cc: Subject: C8 Particle Density Rob, In addition to the particle size distribution, I need a particle density in order to start doing a sensitivity analysis.

AR226-2249 /j?

AR226-2260 C hris E S ho op 02/20/2002 0 5:20 P M ..... ........; _____ ___________ I _____ Tocc: Subject: Robert F Pinchot/DEV/AE/DuPont@DuPont, Debbie J Mulrooney/AE/DuPont@DuPont Robert I Wevodau/SE/DuPont@DuPont, Ravinder Singh/CL/DuPont@DuPont, George L Clowes_Jr/CL/DuPont@DuPont, Stephen J Gissy/AE/DuPont@DuPont Emission Estimates for 2003 Production Rob / Debbie, Here's the file to use for emission estimates based on 2003 production forecasts.

AR226-2259 Debbie J Mulrooney ' 02/20/2002 12:47 PM To: Todd M Krieger/AE/DuPont@DuPont cc: Steven H Swearingen/AE/DuPont@DuPont, Robert F Pinohot/DEV/AE/DuPont@DuPont Subject: Re: Environmental Impact Study Q The new stack height is much higher than what we modeled (85 vs. 55 ft) and the new flow rate is also much higher (12,400 scfm vs. 4710 scfm).

AR226-2527 REMOVING THE 1.4X FACTOR FROM EXPERIMENTAL STATION C-3 IN WATER RESULTS, HERE IS A COMPARISON OF THE MOST RECENT SAMPLES: C-8 SAMPLE EXP ST (PPB) CH2MHILL fPPB) CH2M C9(%) CH2M Cll(%) LAB BLANK --- < 0.1 82 74 TW-27 DUPLICATE 4.7 4.3 2.5 3.2 63 45 75 46 TW-M4 DUPLICATE 1.3 1.7 0.7 0.6 87 72 74 45 TW-331 DUPLICATE 1.0 1.4 0.6 76 49 0.6 85 61 TW-33 DUPLICATE 94 100 75 46 78 34 73 37 NOTE: C9 AND Cll ARE CH2MHILL SURROGATES WITH % RECOVERY SHOW4.

AR226-2551 EID121902 RCRA Facility Investigatioii Results Review March 14,2001 6 L U I0HSV i Introductions Site Background Site Hydrogeology RFI Scope of Work RFI Results Conclusions and Recommendations Wrap-Up 0 8 2 1 1OHSV EID121903 r WToasfahminiglitaornizWe tohrekEs sPiAte/pWhyVsiDcaElPsepttrionjgect team with the cToomsphlaerteedthReCreRsuAltFsaocbiltiatyinIendvefrsotimgatthioenrecently To provide perspective on the RFI results pTrootpercotpioonseoaf hpuamthafnorhweaalrtdhtahnadt wthiell eennvsuirroencmoenntitnued ISntOHSV EID121904 coThvhaeerraD1c0tuePyrieozanerdtsWoanfadisnhwvineesgllttiuognnadtWieornostraoknosdds,mitaeosinsaitwroeersilunl lgt.of caTnohdnettrchooelmpebrnoivngiarroatimnomneeonnfstuIRfrreMopmsroastnietdectStihoWenMaocfUtihvsu.emsiaten hhyedarltahulic DseiftfueePchotyivndetrnainuetsleiscngdcoosinntotgrocfoloprnwrtoiangrudrea.mtoaancdtivmeloynoitpoerriatste the Z8ZII0HSV EID121905 # # M1,2a0n0ufaaccrteusrionngObehgioanRiinve1r9i4n8'western WV Engineering Polymers, Fluoroproducts, and P6dP Engineering plastics (Delrin) - Nylon pellets and filaments (Zytel) - Acrylic resins and molding compounds - Polyvinyl butyral (Butacite) - Teflon & Tefzel Approx. 2,400 employees (DuPont's 2nd largest) C821I0HSV EID121906 WEI IOHSV EID121907 ASI lOU 285 IIM 21908 -1 bI1n9yv8Ee9sP-tiAgCaRotireorgenico(tinVvIIe)IAIorfcet6qiouSniWroinMrg"UVHseSrWifiAca"tipoenrmit issued 1991 and 1992 - Conducted VI MIRnFjaeIrccwthioo1nr9kW9p7lea-lnlEs fProeArmfcooovumerdSmWferonMmteUdcsoo(nnLsViodcIearlaanLtidFonr&e)quired 1998 and 1999 - Conducted RFI 98UI0HSV EID121909 Riverbank Landfill Anaerobic Digestion Ponds Polyacetal Waste Incinerator sntO H S V EID12I910 SWMU LOCATIONS h EID121911 SSCI I0HSV SWMU LOCATIONS Operated from 1948 to mid-1960s Measured 4,500 feet long by 150 feet wide Friivlleerdflsoteoedpplsalionpe separating main plant terrace from Filled with general plant solid waste Closed by covering with soil, vegetation, and rip-rap Today the RBL is densely vegetated Mtcroeenatcthmeyrlenenn-tenscyohswltoemrcidoentsreoellpedwabsytchoellmecatiinonaraenadof 68Z110HSV IID1219X2 ?

m AR226-2749 Copies to Haskell U b r ; i J Uf ^ ,' 02 c S r " y tor Toxicology r * an dh" I n du s t ri a l Medicine __ _______________ HASKELL LABORATORY REPORT NO. 160-69 Material Tested: Ammonium Perfluoro'octanoate Haskell No.: Other Codes ; # v l . (1) PeVilbls eenerat" "ere "sed -- alnm pertluorooctan.af erosols.

AR226-2822 Company Sanitized.

AR226-3091 DuPont HL-1998-01441 HASKELALNLDAIBNODRUASTTORRIAYLFMOERDTIOCIXNIECOLOGY H-227T6O2:FSATTAHTEIACD, AMCIUNTNEO9W6-SH,OPiUmRepShCaRleEspErNomINeGlasTEST PURPOSE: Tthesist cisoancreanntgreaftiionndsinagnsdtuddaytadmeseiagsnuerdemtoenptrsovatidpereadneetestrimmianteedoifnateqruvaatlisc. toxicity using fixed GENERAL INFORMATION WORKMHSRYAAENQSTKOEURENELISYTALTMELNNSSTTUU/CECMMOS0TDBBDEEEESDRER;f::|,Ji/|2H27B6_2 NOTSECUBOBCCNONMAOOOTSIMTTAKREPTMSENOBEPPGIUSORONUIIM'ONSATSRTSKBINIOORTETENYYRRSD;;::| %af TEST CONDITIONS Nominal concentrations tested: 0,0.5,1.0,50,500, and 5000 mg/L.